Esperion Therapeutics Profit Margin

Esperion Therapeutics (ESPR) currently reports a profit margin of 0.12% as of March 2026. That compares with -59.03% in the prior-year period — up 100.2% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Esperion Therapeutics's profit margin history and peer comparisons.

Esperion Therapeutics's profit margin increased from -59.03% to 0.12% — a 100.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Esperion Therapeutics's profit margin of 0.12% is lower than the Healthcare sector average of 15.58%. That is roughly 99.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Esperion Therapeutics's current 0.12% should be judged against Healthcare norms (sector average: 15.58%) and against ESPR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 0.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Esperion Therapeutics, and consider following ESPR for alerts when major investors trade the stock.